Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Golden Developing Solutions, Inc. (DVLP)
Fort Lauderdale, FL, US
Golden Developing Solutions, Inc., together with its affiliated companies, focuses on building and operating an online retail business for products containing cannabidiol (CBD). The company manages a digital storefront that offers a wide range of CBD and hemp oil merchandise, in addition to various health and wellness items. This extensive product line includes vitamins, nutritional supplements, CBD-based tinctures, vape products, soft-gel capsules, and other related goods. Established in 1998, the company officially became Golden Developing Solutions, Inc. in April 2017, having previously traded as Clean Hydrogen Producers, Ltd. Its operations are based in Fort Lauderdale, Florida.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +900.00% | +0.00% | +0.00% | +900.00% | +0.00% | -90.00% | -99.62% | -99.90% | -99.50% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-45.5% Q2'23: -233.3% (vs Q2'22)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%— Q2'23: +19.7% (vs Q2'22)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%— Q2'23: -8.2% (vs Q2'22)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-5.4% Q2'23: +23.9% (vs Q2'22)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+55.4% Q2'23: +84.0% (vs Q2'22)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×192.08× Q2'23: -1.48× (vs Q2'22)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
No beneficial ownership filings recorded.
Institutional Activity (13F)
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ANCORA ADVISORS, LLC | — -50.0K (-100.0%) | — -5.0 (-100.0%) | 0.00% -0.004 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Stavros A. Triant | President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer & Chairman | 138.0K | male |
| Harald Wirth | Chief Operating Officer | — | — |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DVLP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
